Imeglimin hydrochlorideAntidiabetic agent CAS# 775351-61-6 |
- DCC-2618
Catalog No.:BCC1520
CAS No.:1225278-16-9
- Imatinib Mesylate (STI571)
Catalog No.:BCC1115
CAS No.:220127-57-1
- Motesanib
Catalog No.:BCC1776
CAS No.:453562-69-1
- OSI-930
Catalog No.:BCC1253
CAS No.:728033-96-3
- Masitinib (AB1010)
Catalog No.:BCC1260
CAS No.:790299-79-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 775351-61-6 | SDF | Download SDF |
PubChem ID | 54763513 | Appearance | Powder |
Formula | C6H13N5 | M.Wt | 155.2 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | EMD 387008 hydrochloride | ||
Solubility | DMSO : 25 mg/mL (130.44 mM; Need ultrasonic) | ||
Chemical Name | (4R)-6-N,6-N,4-trimethyl-1,4-dihydro-1,3,5-triazine-2,6-diamine;hydrochloride | ||
SMILES | CC1N=C(NC(=N1)N(C)C)N.Cl | ||
Standard InChIKey | UXHLCYMTNMEXKZ-PGMHMLKASA-N | ||
Standard InChI | InChI=1S/C6H13N5.ClH/c1-4-8-5(7)10-6(9-4)11(2)3;/h4H,1-3H3,(H3,7,8,9,10);1H/t4-;/m1./s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Imeglimin hydrochloride is the first antidiabetic compound that induces an increase in mitochondrial phospholipid composition, contributing to improvements in hepatic mitochondrial function.In Vitro:Imeglimin also reduces reactive oxygen species production and increases mitochondrial DNA. Imeglimin effects on mitochondrial phospholipid composition can participate in the benefit of Imeglimin on mitochondrial function. Imeglimin increases mtDNA content without modifying PGC1α expression. Imeglimin amplifies the effects of high-fat, high-sucrose diet (HFHSD) on both cardiolipin and phosphatidylserine (PS) content, whereas it tends to restore phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylinositol (PI) content to normal values in HFHSD mitochondria
[1].In Vivo:Imeglimin is administered orally at 200 mg/kg b.i.d. during the last 6 weeks of the HFHSD feeding protocol. A slight decrease in body weight and food intake associated with some diarrhea is observed but only during the first few days of treatment. Imeglimin significantly decreases hyperglycemia, restores normal glucose tolerance, and improves insulin sensitivity[1]. References: |
Imeglimin hydrochloride Dilution Calculator
Imeglimin hydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 6.4433 mL | 32.2165 mL | 64.433 mL | 128.866 mL | 161.0825 mL |
5 mM | 1.2887 mL | 6.4433 mL | 12.8866 mL | 25.7732 mL | 32.2165 mL |
10 mM | 0.6443 mL | 3.2216 mL | 6.4433 mL | 12.8866 mL | 16.1082 mL |
50 mM | 0.1289 mL | 0.6443 mL | 1.2887 mL | 2.5773 mL | 3.2216 mL |
100 mM | 0.0644 mL | 0.3222 mL | 0.6443 mL | 1.2887 mL | 1.6108 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
AMP-activated protein kinase (AMPK) acts as an integrator of regulatory signals to monitor systemic and cellular energy status. Imeglimin targets on three main organs involved in glucose homeostasis: liver, muscle and the pancreas and thus has a distinct mode of action in comparison to existing Type 2 diabetes treatments.
In vitro: In liver mitochondria, imeglimin redirects substrate flows in favor of complex II. Moreover, imeglimin inhibits complex I and restores complex III activities, advicing an increase of fatty acid oxidation, further supported by an increase in hepatic 3-hydroxyacetyl-CoA dehydrogenase activity and acylcarnitine profile. Imeglimin was also found to reduce the production of reactive oxygen species and increases the DNA of mitochondrial [1].
In vivo: A previous study used a model of 16-week high-fat, high-sucrose diet (HFHSD) mice to characterize imeglimin’s antidiabetic effects. Six-week imeglimin treatment could decrease glycemia, restore normal glucose tolerance, and improve insulin sensitivity, body weights and food intake significantly. This was associated with an increase of insulin-stimulated protein kinase B phosphorylation in the liver and muscle. In conclusion, imeglimin could normalize glucose tolerance and insulin sensitivity via preserving mitochondrial function from oxidative stress and favoring lipid oxidation in liver of HFHSD mice [1].
Clinical trial: Imeglimin is an experimental drug being developed as an oral anti-diabetic. Imeglimin is in development (completed phase IIb clinical trials) for use both as monotherapy and in combination with other type-2 diabetes treatments. Various research protocols are being known through various scientists. Early studies showed that imeglimin is as effective as metformin in regulating glycaemic control.
Reference:
[1] Vial G, Chauvin MA, Bendridi N, Durand A, Meugnier E, Madec AM, Bernoud-Hubac N, Pais de Barros JP, Fontaine É, Acquaviva C, Hallakou-Bozec S, Bolze S, Vidal H, Rieusset J.Imeglimin Normalizes Glucose Tolerance and Insulin Sensitivity and Improves Mitochondrial Function in Liver of a High-Fat High-Sucrose Diet Mice Model. Diabetes. 2014. pii: db141220
- PTC124 (Ataluren)
Catalog No.:BCC3881
CAS No.:775304-57-9
- DL-m-Tyrosine
Catalog No.:BCC3332
CAS No.:775-06-4
- Phenylpiracetam
Catalog No.:BCC1859
CAS No.:77472-70-9
- Pimobendan hydrochloride
Catalog No.:BCC4175
CAS No.:77469-98-8
- KM 11060
Catalog No.:BCC7578
CAS No.:774549-97-2
- 5-Androsten-3β-ol-17-one ethyleneketal
Catalog No.:BCC8738
CAS No.:7745-40-6
- Episesartemin A
Catalog No.:BCN7239
CAS No.:77449-31-1
- Sesartemin
Catalog No.:BCN4779
CAS No.:77394-27-5
- Drimiopsin D
Catalog No.:BCN4326
CAS No.:773850-91-2
- Drimiopsin C
Catalog No.:BCN4325
CAS No.:773850-90-1
- Triacetylpseurotin A
Catalog No.:BCN6916
CAS No.:77353-57-2
- Acamprosate calcium
Catalog No.:BCC1327
CAS No.:77337-73-6
- Imeglimin
Catalog No.:BCC4221
CAS No.:775351-65-0
- Corylifol A
Catalog No.:BCN3198
CAS No.:775351-88-7
- Corylifol B
Catalog No.:BCN3199
CAS No.:775351-90-1
- Corylifol C
Catalog No.:BCN3200
CAS No.:775351-91-2
- (20R)-Protopanaxdiol
Catalog No.:BCN1078
CAS No.:7755-01-3
- Ingenol-5,20-acetonide
Catalog No.:BCN2960
CAS No.:77573-43-4
- Ingenol-3,4:5,20-diacetonide
Catalog No.:BCN2959
CAS No.:77573-44-5
- Nestoron
Catalog No.:BCC1797
CAS No.:7759-35-5
- Isoscopoletin
Catalog No.:BCN4582
CAS No.:776-86-3
- Fmoc-HomoArg-OH
Catalog No.:BCC2645
CAS No.:776277-76-0
- 1,4,5,6-Tetrahydroxy-7,8-diprenylxanthone
Catalog No.:BCN1358
CAS No.:776325-66-7
- Toddanone
Catalog No.:BCN3430
CAS No.:77636-08-9